Study investigators reported at the 2013 San Antonio Breast Cancer Symposium that the addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response (pCR) rates in patients with triple-negative breast cancer (TNBC).
According to the results of a prospective, randomized, controlled trial, in women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS).
Findings reported at the 2013 San Antonio Breast Cancer Symposium showed that PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR).
A new study reported at the 2013 San Antonio Breast Cancer Symposium shows that a prescribed exercise program reduces joint pain in breast cancer survivors taking aromatase inhibitors (AIs), with pain reductions observed at all levels of exercise.
According to newly reported findings from the International Breast Cancer Intervention Study II (IBIS-II), anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.
In women with hormone receptor-positive, HER2-negative metastatic breast cancer, the addition of dasatinib to standard aromatase inhibitor therapy with letrozole doubled progression-free survival (PFS) compared with letrozole alone.
A combination of rituximab (Rituxan) and the PI3K-delta inhibitor idelalisib was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL).
At the 55th Annual Meeting of the American Society of Hematology (ASH), several trials of ibrutinib both alone and in combination with currently used therapies for patients with chronic lymphocytic leukemia (CLL) were presented.
Results of a phase II trial showed that when treated with a reduced dose of the oral FLT3 receptor tyrosine kinase inhibitor quizartinib, nearly half of patients with relapsed/refractory acute myelogenous leukemia (AML) had complete remissions.
If treated with hormonal therapy and considered to be at low risk for breast cancer recurrence, women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy (RT) after breast conserving surgery.
Brentuximab vedotin, an anti-CD30 monoclonal antibody, has demonstrated antitumor activity in the setting of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and has generated responses across a broad range of CD30 expression, including low or undetectable CD30 expression. Data from an ongoing phase II study were presented by Nancy Bartlett, MD, at the 55th annual meeting of the American Society of Hematology (ASH).
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
According to results from the large randomized BETH trial, bevacizumab did not improve invasive disease-free survival (IDFS) or overall survival (OS) when added to adjuvant therapy for HER2-positive breast cancer.
Neil M. Iyengar, MD, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.
Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast can
Pathologic complete response (pCR) to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.
HER2-positive breast cancer may not only be immunogenic but treatment with trastuzumab may also relieve suppression of antitumor immunity, according to new data presented by Sherene Loi, MD, PhD.
According to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium, the benefit of screening mammography is more consistent across studies than has previously been thought.
Jennifer E. Amengual, MD, discusses the study she presented at the 2013 American Society of Hematology (ASH) Annual Meeting. The trial analyzed dual targeting with the HDAC inhibitor ACY-1215 and bortezomib in preclinical models of lymphoma.
An investigator reported at the 55th annual meeting of the American Society of Hematology (ASH) that imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.
In patients with previously untreated chronic lymphocytic leukemia (CLL) who are considered inappropriate for fludarabine, the addition of ofatumumab to chlorambucil improves clinical outcomes and is tolerable irrespective of patient age or fitness.
Steven Treon, MD, PhD, reported that ibrutinib rapidly reduced serum immunoglobulin M (IgM) levels and improved hematocrit levels in patients with relapsed or refractory Waldenström’s macroglobulinemia (WM), and the responses to ibrutinib were durable.
According to preliminary results of a phase I clinical trial, nearly half of patients with relapsed or refractory CLL attained objective responses when treated with IPI-145, an oral inhibitor of PI3K-delta and -gamma.
According to data presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, a first-in-class targeted agent demonstrated activity in patients with relapsed and refractory multiple myeloma.
Shaji K. Kumar, MD, discusses the results of a phase II trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib.
An orally bioavailable selective inhibitor of the Bcl-2 protein induced remissions in patients with relapsed/refractory CLL and SLL.
A randomized trial showed that patients with CLL and major comorbidities had significantly better outcomes when treated with obinutuzumab, an anti-CD20 monoclonal antibody, instead of rituximab.
In patients with transplant-ineligible NDMM, the combination of continuous lenalidomide and low-dose dexamethasone (continuous Rd) extends PFS and trends toward improving OS compared with the standard combination of MPT.
CRs were seen in a group of high-risk patients following intervention in early or “smoldering†myeloma with a three-drug regimen, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.